86. Effect of Oral Fosfomycin Compared to the Intravenous Beta Lactam/Beta-Lactamase Inhibitor or Carbapenem in Step-down Treatment of Patients with Complicated Urinary Tract Infection due to Extended-Spectrum Beta-Lactamase (ESBL) Producing Enterobacteriaceae: A Multicenter, Open-label, Randomized Controlled, Non-inferiority Trial

BACKGROUND: The widespread use of carbapenem in the treatment of UTIs caused by ESBL-producing enterobacteriaceae has led to the emergence of carbapenem resistant enterobacteriaceae. In this randomized controlled trial, we aimed to determine whether oral fosfomycin was inferior to carbapenems or bet...

Descripción completa

Detalles Bibliográficos
Autores principales: Seo, Jun-won, Young Kim, Da, Yoon, Youngmin, Sang Lyu, Young, Sub Na, Yong, Sik Moon, Do, Ra Yun, Na, Seok Kim, Min, Kim, Jeong-Han, Woon Bae, Sang, Hur, Jian, Hyung Kim, Min, Soo Park, Yoon, Kim, Heejung, Lee, Hyungdon, Jang, Hee-Chang, Kim, Dong-Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678117/
http://dx.doi.org/10.1093/ofid/ofad500.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678117/
http://dx.doi.org/10.1093/ofid/ofad500.002

Ejemplares similares